Showing results (41-50 of 410) with videos related to
Sort By:
Pageof 41
Molecular Cancer Therapeutics|June 2, 2012
Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathwaysXinqi Wu, Jingjing Li, Meijun Zhu, et al.Journal for Immunotherapy of Cancer|July 4, 2014
Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?Mizuki Nishino, Maria Gargano, Margaret Suda, et al.The Oncologist|June 19, 2013
Ipilimumab and its toxicities: a multidisciplinary approachLeslie A Fecher, Sanjiv S Agarwala, F Stephen Hodi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2012
The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibitionXiaofeng Jiang, Jun Zhou, Anita Giobbie-Hurder, et al.Plos One|January 19, 2012
The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanomaXinqi Wu, Meijun Zhu, Jonathan A Fletcher, et al.American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination TherapiesMeenal Datta, Lisa M Coussens, Hiroyoshi Nishikawa, et al.JAMA Oncology|August 20, 2016
Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysisMizuki Nishino, Anita Giobbie-Hurder, Hiroto Hatabu, et al.Cancer|February 13, 2013
Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanomaJeffrey S Weber, Reinhard Dummer, Veerle de Pril, et al.The Journal of Clinical and Aesthetic Dermatology|November 17, 2016
Systemic Therapies for Late-stage MelanomaPeter W Hashim, Philip Friedlander, Gary GoldenbergCancer Immunology Research|November 13, 2014
Immunity to the vacuolar ATPase complex accessory unit ATP6S1 in patients with malignant melanomaJun Zhou, Meghna Gupta, Xinqi Wu, et al.Pageof 41